

Pharmaderm Co SAE  
BALANCE SHEET  
AS AT Mar 31, 2024  
Amount in Local Currency

ASSETS	Notes	As at 31.03.2024		As at 31.03.2023	
<b>ASSETS</b>					
<b>1. Non-Current Assets</b>					
(a) Property, Plant and Equipment	3.1	2,224,258		2,316,550	
(b) Capital Work-in-Progress	3.1	-		-	
(c) Investment Property	3.2	-		-	
(d) Goodwill on Consolidation	3.3				
(e) Right of Use Assets					
(f) Intangible Assets	3.3	-		-	
(g) Intangible Assets under Development	3.3	-		-	
(h) Financial Assets					
(i) Investments	3.4	-		-	
(ii) Loans	3.5	-		-	
(iii) Others	3.6	-		-	
(i) Other Non-Current Assets	3.7	256,512	2,480,770	256,512	2,573,062
<b>2. Current Assets</b>					
(a) Inventories	3.8	-		-	
(b) Financial Assets					
(i) Investments	3.4	-		-	
(ii) Trade Receivables	3.9	-		-	
(iii) Cash and Cash Equivalents	3.10	330,270		283,251	
(iv) Bank Balance other than (iii) above	3.11	1,060,401		1,052,132	
(v) Loans	3.12	-		-	
(vi) Other Financial Assets	3.13	-		-	
(c) Current Tax Assets (Net)	3.14	-		-	
(d) Other Current Assets	3.15	938,682	2,329,353	938,693	2,274,076
<b>Total Assets</b>			<b>4,810,123</b>		<b>4,847,138</b>
<b>EQUITY AND LIABILITIES</b>					
<b>EQUITY</b>					
(a) Equity Share Capital	3.16	2,126,000		2,126,000	
(b) Other Equity	3.17	(87,131,683)	(85,005,683)	(55,793,557)	(53,667,557)
<b>1. Non-Current Liabilities</b>					
(a) Financial Liabilities					
(i) Borrowings	3.18	89,451,468		58,338,848	
(ii) Other Financial Liabilities	3.19	-		-	
(b) Provisions	3.20	-		-	
(c) Deferred Tax Liabilities (Net)	3.21	-		-	
(d) Other Non-Current Liabilities	3.22	-	89,451,468	-	58,338,848
<b>2. Current Liabilities</b>					
(a) Financial Liabilities					
(i) Borrowings	3.23	-		-	
(ii) Trade Payables	3.24				
Total outstanding dues of Micro, Small & Medium Enterprises (MSME)		-		-	
Total outstanding dues of creditors Other than MSME		364,254		175,762	
(iii) Other Financial Liabilities	3.25	-		-	
(b) Other Current Liabilities	3.26	84		84	
(c) Provisions	3.27	-		-	
(d) Current Tax Liabilities (Net)					
			364,338		175,846
<b>Total Equity and Liabilities</b>			<b>4,810,123</b>		<b>4,847,138</b>

*Amitabh Goenka*

Amitabh Goenka  
Director  
Date-14-May-24



Pharmaderm Co SAE  
**STATEMENT OF PROFIT AND LOSS ACCOUNT**  
 Twelve Month Mar'24  
 Amount in Local Currency

Particulars		Twelve Month Mar'24	Twelve Month Mar'23
<b>Income</b>			
Revenue from Operations		-	-
Other Income		8,269	36,702
<b>Total Income</b>	<b>(A)</b>	<b>8,269</b>	<b>36,702</b>
<b>Expenses</b>			
Cost of Materials Consumed		-	-
Purchases of Stock-in-Trade			
(Increase)/Decrease in Inventories of Finished Goods, Stock in Trade and Work-in-Progress		-	-
Excise duty on sale of Goods			
Employee Benefits Expense		67,720	69,470
Other Expenses		31,186,383	24,096,888
<b>Total Expenses Before Interest, Depreciation, Amortisation and Tax</b>	<b>(B)</b>	<b>31,254,103</b>	<b>24,166,358</b>
Earning Before Interest, Depreciation, Amortisation and Tax	<b>(A-B)</b>	(31,245,834)	(24,129,656)
Finance Costs	<b>(C)</b>	-	-
Depreciation, Amortisation & Impairment Expense:			
a) Amortisation & Impairment of Intangible Assets		-	-
b. Depreciation on Right of use assets		-	-
c) Depreciation of Tangible Assets		92,292	92,293
	<b>(D)</b>	<b>92,292</b>	<b>92,293</b>
<b>Total Expenses</b>	<b>(B+C+D)=E</b>	<b>31,346,395</b>	<b>24,258,651</b>
<b>Profit Before tax and exceptional items</b>	<b>(A-E)=F</b>	(31,338,126)	(24,221,949)
Exceptional items	<b>(G)</b>		
<b>Profit Before tax</b>	<b>(F-G)=H</b>	(31,338,126)	(24,221,949)
<b>Tax Expense:</b>	<b>(I)</b>		
Current Tax (MAT)			
Provision of Earlier Years			
MAT Credit Entitlement			
Deferred Tax charge			
<b>Profit for the year</b>	<b>(H-I)=J</b>	(31,338,126)	(24,221,949)
<b>Other Comprehensive Income</b>			
Items that will not be reclassified to Profit or Loss in subsequent periods			
Equity Instrument through Other Comprehensive Income (net of tax)			
Remeasurement of the net defined benefit liability/ asset (net of tax)			
Income Tax Effect			
<b>Total Other Comprehensive Income, net of tax</b>		-	-
<b>Total Comprehensive Income for the year</b>		<b>(31,338,126)</b>	<b>(24,221,949)</b>

*Amitabh Goenka*  
 Amitabh Goenka  
 Director  
 Date-14-May-24




Pharmaderm Co SAE

Notes to Financial statements  
3.1 Property Plant & Equipment (Current Year)

Particulars	Gross Block			Depreciation		Net Block			
	As at 1.4.2023	Additions	Disposals/ Transfer	As at 31.03.2024	As at 1.4.2023	For the Period	Disposals/ Transfer	As at 31.03.2024	As at 31.3.2023
Land									
Leasehold Freehold	1,216,431			1,216,431	-			1,216,431	1,216,431
Building (including roads)*	2,052,044			2,052,044	981,229	62,989		1,044,218	1,070,815
Plant & Equipment	291,045			291,045	288,653	2,392		291,045	2,392
Furniture & Fixture	250,175			250,175	223,288	26,887		250,175	26,887
Office Equipment									
Computer	2,714			2,714	2,689	24		2,713	25
Motor Vehicles									
<b>Property, Plant &amp; Equipment Total</b>	<b>3,812,409</b>	<b>-</b>	<b>-</b>	<b>3,812,409</b>	<b>1,495,859</b>	<b>92,292</b>	<b>-</b>	<b>1,588,151</b>	<b>2,316,550</b>
Capital Work- In-Progress									
<b>Total</b>	<b>3,812,409</b>	<b>-</b>	<b>-</b>	<b>3,812,409</b>	<b>1,495,859</b>	<b>92,292</b>	<b>-</b>	<b>1,588,151</b>	<b>2,316,550</b>

Attack C/L



**Pharmaderm Co SAE**  
**Notes to Financial Statements**

**3.7 Other Non-current Assets**

	As at 31.03.2024	As at 31.03.2023
<b>Unsecured, Considered Good unless otherwise stated</b>		
Capital Advances		
Deposit with Government authorities	256,512	256,512
Prepaid Expenses		
Advance income tax ( Net of Provision)		
Incentives Receivables		
Less: Provision for Doubtful Receivables		
<b>Total</b>	<b>256,512</b>	<b>256,512</b>

**3.10 Cash and Cash Equivalents**

	As at 31.03.2024	As at 31.03.2023
<b>Cash and Cash Equivalents</b>		
Balances with Banks	329,120	282,101
Fixed Deposits with Banks (Original Maturity of less than 3 Months)		
Cash on hand	1,150	1,150
Cheques in hand		
<b>Total</b>	<b>330,270</b>	<b>283,251</b>

**3.11 Other Bank Balances**

	As at 31.03.2024	As at 31.03.2023
<b>At amortised cost</b>		
<b>Other Bank Balances</b>		
Unpaid Dividend account		
Deposit with Original maturity of more than 3 months but less than 12 months	1,060,401	1,052,132
<b>Total</b>	<b>1,060,401</b>	<b>1,052,132</b>

**3.15 Other Current Assets**

	As at 31.03.2024	As at 31.03.2023
<b>Unsecured, considered good</b>		
Advances other than Capital Advances		
For goods and services	490,332	490,332
To employees		
Balances with Excise and Sales Tax Department	448,350	448,350
Prepaid Expenses	-	11
<b>Total</b>	<b>938,682</b>	<b>938,693</b>

**3.16 Equity Share Capital**

	As at 31.03.2024	As at 31.03.2023
<b>Authorised</b>		
<b>Issued</b>	2,126,000	2,126,000
<b>Subscribed &amp; Paid up*</b>	2,126,000	2,126,000
<b>Total Issued, Subscribed and Fully paid up Share Capital</b>	<b>2,126,000</b>	<b>2,126,000</b>

*Antall Cl*



**3.17 Other Equity**

	As at 31.03.2024	As at 31.03.2023
<b>Retained Earnings</b>		
Opening balance	(55,793,556.51)	(34,437,355)
Net Profit for the Year	(31,338,126)	(24,221,949)
Remeasurements of the Net Defined Benefit Plans (net of tax)		
IND AS 115 Impact		
Income Tax Effect		
Final Dividend#		
Corporate Dividend Tax#		
Closing Balance	(87,131,683)	(58,659,304)
<b>Other Comprehensive Income</b>		
Opening Balance		2,865,747
Equity Instruments through Other Comprehensive Income		
Income Tax Effect		
Closing Balance	-	2,865,747
<b>Other Reserves</b>		
<b>Total</b>	<b>(87,131,683)</b>	<b>(55,793,557)</b>

**3.18 Borrowings**

	As at 31.03.2024	As at 31.03.2023
<b>At amortised cost</b>		
<b>Unsecured</b>		
<b>Loan from related party</b>		
<b>(Emami Overseas FZE -Holding Company)</b>	89,451,468	58,338,848
		-
<b>Total</b>	<b>89,451,468</b>	<b>58,338,848</b>

**3.24 Trade Payables**

	As at 31.03.2024	As at 31.03.2023
<b>At amortised cost</b>		
Total outstanding dues of Micro, Small & Medium Enterprises (MSME)		
Total outstanding dues of creditors Other than MSME	364,254	175,762
<b>Total</b>	<b>364,254</b>	<b>175,762</b>

**3.26 Other Current Liabilities**

	As at 31.03.2024	As at 31.03.2023
Deferred government grant		
Refund Liabilities		
Advance from Customers		
Duties & Taxes	84	84
<b>Total</b>	<b>84</b>	<b>84</b>

*Aashish Ch*



**Pharmaderm Co SAE**  
**Notes to Financial Statements**

**3.29 Other Income**

	Twelve Month Mar'24	Twelve Month Mar'23
<b>Interest Received on financial assets carried at amortised cost</b>		
Loans & Deposits	8,269	36,702
Others		
Dividend Income from equity investment carried at cost		
Dividend Income from equity investment carried at fair value through OCI		
<b>Income received on investment carried at fair value through Profit or Loss</b>		
Dividend from investment in mutual funds		
Profit/ (loss) on Sale of mutual funds		
Profit/ (loss) on Derivative instruments		
Profit/ (loss) on Sales of Property, Plant & Equipments		
Rent and Maintenance Charges Received		
Sundry Balances Written Back		
Miscellaneous Receipts		
Net foreign exchange gain	-	
<b>Total</b>	<b>8,269</b>	<b>36,702</b>

**3.32 Employee Benefit Expenses**

	Twelve Month Mar'24	Twelve Month Mar'23
Salaries and Wages	67,720	69,470
Staff Contribution to Provident and Other Funds		
Gratuity Expenses		
Welfare Expense		
<b>Total</b>	<b>67,720</b>	<b>69,470</b>

**3.34 Other Expenses**

	Twelve Month Mar'24	Twelve Month Mar'23
Consumption of Stores and Spare parts		
Power and Fuel	20,680	13,981
Rent		
Repairs & Maintenance :		
Building		
Machinery		
Others		
Insurance		
Rates and Taxes	-	-
Freight & Forwarding		
Directors' Fees and Commission		
Advertisement & Sales Promotion		
Packing Charges		
Commission		
Loss on Sale/Disposal of Property, Plant & Equipments		
Bank charges	1,883	310
Legal and Professional Fees	264,000	254,106
Travelling and Conveyance	5,510	5,565
Expenditure on CSR Activities		
Miscellaneous Expenses	4,449	4,140
Net foreign exchange loss	30,889,862	23,818,786
<b>Total</b>	<b>31,186,383</b>	<b>24,096,888</b>

**Depreciation, Amortisation & Impairment Expense**

	Twelve Month Mar'24	Twelve Month Mar'23
a. Amorisation & Impairment of Intangible Assets	-	-
c. Depreciation of Other Assets	92,292	92,293
<b>Total</b>	<b>92,292</b>	<b>92,293</b>

*Attal CL*



Reporting Company Name	Related Party Name	Nature of Relationship	Transaction Details	Item Type	For PL Items Twelve Month Mar'24	For BS Items As at 31.03.2024
Pharmaderm Company SAE	Emami Overseas FZE	Parent Company	Loan Payable	BS		89,451,468

*Attach C/-*

